The last few years have seen a growing interest in stem cell research. The media has helped to keep attention to the subject making i popular as therapeutic cloning. A number of studies highlighted the importance of stem cells as prospective therapy for neurodegenerat conditions. The possibility of successful treatment for such pathologies using stem cells has raised enormous hope. Whilst in so countries biotechnologists have realised the commercial potential of the field, human stem cell research and its clinical applicati have constantly been subject of ethical and legal debate. The present review brings an overview of recent aspects of stem cell resea for central nervous system disorders, with special attention to Parkinson's and Alzheimer's diseases, cerebral ischemic insult and spi cord injury. Furthermore, the ethical implications regarding the use of embryonic stem cells as a fundamentally more promising c type are discussed.
Introduction
A scientific revolution has recently begun involving pre-clinical and clinical trials targeting diseases of the central nervous system (CNS). To a great extent, this is due to evidence that the adult brain contains cells capable of producing new neurones, as well as reports showing that implanted stem cells may substitute lost or malfunctioning cells in the CNS. Thus, untreatable pathologies, such as spinal cord injury, cerebral ischemia, and Parkinson's and Alzheimer's diseases, may become candidates for more permanent treatments than those offered by conventional pharmacological approaches.
Stem cells (SC's) are a very special type of cell with a great capacity for differentiation, migration and mitosis. There are, basically, two types of SC's: embryonic and adult. Embryonic SC's are found in the initial period of embryonic development, shortly after fertilization of the egg and have the capacity to differentiate into any tissue of the body (Zeng, 2006; Menendez, 2006) . Adult SC's present some characteristics of immature cells, such as a high capacity for cellular division and differentiat (Huh, Pan, Mysorekar, & Mills, 2006; Reubinoff et 2001; Rogers & Casper, 2004; Roisen et al., 2001; Ste Rozen, Kaufman, & Lerner, 2006; Stein, Zhu, & Emers 2004; Tarnowski & Sieron, 2006; Wang et al., 2004) .
In recent years, our knowledge of the functional a morphological aspects of these cells and their cult conditions has increased considerably. This has ma it possible to isolate and proliferate these cells in vi (Thomson & Odorico, 2000) , as well as to genetica modify them (Gokhan, Song, & Mehler, 1998; Him et al., 2001; Nakafuku & Nakamura, 1995; Redi Lendahl, & McKay, 1991) . Several laboratories ha investigated the implantation of these cells in anim models of neurodegenerative diseases and their respon to growth factors. Also, the increasing knowledge of physiopathology of many neurodegenerative conditio such as Alzheimer's disease, has prompted new treatm possibilities using stem cells (Oliveira & Hodges, 200 Self-renewal and differentiation are associated with the capacity to migrate to the parenchyma, observed in embryonic SC's after implantation. These properties enable the use of SC's in cell replacement therapy (Abranches, Bekman, Henrique, & Cabral, 2003) . However, several issues have yet to be understood before clinical trials can start. Standardised immunosuppressive protocols are required in order to prevent cell rejection in allogenic transplants. There are also concerns regarding the condition of the implanted cells and what line of differentiation they may adopt. Another concern is the currently limited knowledge of cell culture heterogeneity and growth factors (Schuldiner, Yanuka, Itskovitz-Eldor, Melton, & Benvenisty, 2000) . In vitro studies have shown a high rate of differentiation variability of primate embryonic stem cells (Pau & Wolf, 2004) . Also, the adequacy of animal models of some CNS pathologies often prohibits adequate pre-clinical scrutiny, increasing the risks of translating experimental studies for human clinical trials (McCabe et al., 2000) .
The central nervous system and its stem cells
A long-held belief stated that the production of new neuronal cells in the CNS could only occur during the embryonic development, and not in the adult brain (Gage, 1998; Gage, 2000) . This assumption by Ramón y Cajal (apud Gage, 1998) was only recently brought into question after evidence of selfrenewing and multipotent adult brain stem cells (Gage, 1998; Gage, 2000) . Since these cells are not capable of halting the degeneration of the brain, such evidence failed to inspire hope for their therapeutic application. On the other hand, the brain's capacity to maintain self-renewing cells supports the idea that implanted cells have a nourishing environment in which to develop.
The brain and the spinal cord, which together comprise the CNS, are delicate and complex structures susceptible to various types of insults. From the early development to the aging adult, neuronal death may cause devastating brain damage with eventual impact on all aspects of human functioning. Since the brain controls all higher mental and cognitive functions, a lack of recovery in the CNS challenges health care professionals. Therefore, the alleviation of such damage is a major therapeutic objective.
The most important role of neural networks in the brain is to transmit signals and allow communication between cells and, ultimately, structures involved in functions, such as memory or motor activity. For instance, death or dysfunction of dopaminergic neurones in the nigrostriatal pathway is the core pathology in Parkinson's disease. Consequently, the main direction of current therapy is the pharmacological approach.
Neural stem cells
During the foetal stage, SC's of the neural lineage are developing abundantly and although they can be found in the adult brain, it is not an easy task. Some reports have Ray, & Fisher, 1995; Galvin & Jones, 2002; Song, Steve & Gage, 2002) . These cells are called neural stem cells a are non-differentiated cells with high proliferation and se renewing capacity that will give origin to all CNS ce including neurones (Gage, 2000) . In all stages of developme neural stem cells lie on the basal layer of the SVZ. In this nic stem cells divide and give rise to progenitor cells committed the neural lineage. It is from the SVZ that they will migr to different areas of the developing brain (Gage, 1998; Ga 2002; Garcia-Verdugo et al., 2002) . During differentiati neural SC's acquire markers that respond to the develop CNS environment and determine their consequent linea (Gage, 1998; Gage, 2002; Garcia-Verdugo et al., 2002) .
The differentiation capacity of neural SC's has been debat The multipotential capacity of these cells has been sho in several studies (Oliveira, Grygorian, & Hodges, 200 Sinden et al., 1997; Vescovi & Snyd 1999) . It has also been demonstrated that neural SC's are a to differentiate into non-neural cell lineages, such as blo (Bjornson, Rietze, Reynolds, Magli, & Vescovi, 1999) , a the reverse is also possible, as epithelial cells in the appropri condition may differentiate into neuronal cells (Joannides et 2004) . Although the capacity of embryonic SC's is recogniz as promising for future therapeutics, SC's from other origi such as bone marrow, can also be of great value.
Other sources of non-embryonic stem cells
Due to practical and ethical implications in obtaining ce from embryos, the research in this field is being restricted. several countries, research on embryonic material is limited a very few available cell lines. Other countries have restrict laws for the use of embryonic material. Ethical issues are a constantly raised on the basis of religious or philosophi arguments regarding the use of human tissue for resear Although research on embryonic stem cells is considered v important for medical purposes, the possibility of finding ce with a similar potential in adult organisms has opened a vari of possible sources for stem cells.
In any case, research on embryonic, foetal or adult st cells is being carried out in several laboratories and m determine the future of cell transplantation. Embryo stem cells are generally cells that have been harvested fr embryos up to the 10 th day after fertilization. These ce are usually considered to be the most flexible and capa of differentiation: totipotent. After this initial time, bef birth, the material obtained for research or transplantat is regarded as foetal tissue. Although it is possible to obt cells from the umbilical cord, all SC's obtained from bi to adulthood are called adult stem cells.
Umbilical cord blood
Cells collected from the umbilical cord blood are a promis source of cells for grafting. Some reports have shown that umbilical cord blood contains cells that may express neuro stem cells (Wang et al., 2004) and has compelling potential for therapeutic use in neurological diseases due to the ability of these cells to differentiate into neural lineages (Buzanska et al., 2002; Jeong et al., 2004; Li et al., 2004; McGuckin, Forraz, Allouard, & Pettengell, 2004; Rogers & Casper, 2004; Sanchez-Ramos et al., 2001) .
Bone marrow stem cells
Much of the research into adult SC's is carried out with bone marrow cells. It has been shown that these cells have the potential to proliferate and differentiate into several types of cells. Bone marrow stem cells (BMSC) have two major advantages over other cell sources: accessibility and immunological advantages. The use of BMSC's for grafts circumvents the ethical concerns attached to the use of embryonic cells. It also brings technical and practical solutions, such as simpler cell collection, since it has been practiced for some time already in bone marrow transplants. The cells could also be obtained from the recipient, unless the treatment is for a genetic disease (Filip, Mokry, Karbanova, Vavrova, & English, 2004; Hermann et al., 2004; Jori et al., 2004; Tondreau et al., 2004) .
Stem cells and neural transplantation
Over a hundred years ago, the first attempts at grafting CNS tissue in the adult brain were reflected in the pioneering studies of Walter G. Thompson in 1890, where cats and dogs were used to investigate the survival of grafted tissue. Thompson wrote: "Of course, I had no expectation of being able to restore abolished function by the operation, but the question of vitality of the brain tissue and the course of its degeneration is a subject which is of very wide interest." It has, indeed, shown a proof of principle.
Nevertheless, it was only in the last 30 years that the technology required for successful transplantation of CNS tissue has been developed. In 1976, a work published by Lund and Hauschka showed that superior collicular fragments transplanted from foetal to newborn rat brains developed a complex internal organization and received visual afferents from the host brain (Lund & Hauschka, 1976) . This study highlighted the possibility that intracerebral CNS-derived transplants may be able to integrate with damaged neural tissue.
Other studies from the same decade showed successful transplantation of immature central and peripheral neurons into the CNS (Stenevi, Bjorklund, & Svendgaard, 1976) . At that early stage, success in neural transplantation was limited to transplant survival. However, it was becoming clear that implants of neural tissue into damaged CNS could ameliorate symptoms of motor and cognitive dysfunction.
When the donor tissue is immature, from foetal or neonatal sources, and the site of implantation is richly vascularised, the chances of transplant survival are hugely increased (Barker & Dunnet, 1999) . Promising results from SC research have shown that stem cell grafts can successfully recover animal models of Parkinson's disease (Bjorklund et al., 2002) , Alzheimer's and plasticity has changed from Cajal's non-regenerating vi to an exciting perspective of therapeutic regeneration. The of stem cells has begun.
Prospective cell therapy for Parkinson disease
Parkinson's disease (PD) is a progressive neurodegenerat disorder, which affects movement control, including speech a 'body language'. Although the incidence is higher in the elde population, more than one in ten sufferers are diagnosed bef the age of 50 (Morens et al., 1996) . This chronic incura disease occurs due to a malfunction of dopaminergic cells the striatal pathway or cell death in the substantia nigra. T regions innervated by these dopaminergic projections ha connections to cortical areas responsible for fine movem control (Isacson, 2002) .
The World Health Organization has estimated an incre in the number of PD patients, as the general population gro older (Baker & Gershanik, 2006) . Because of this growth is imperative to promote the assessment of health needs a reinforce research into new therapeutic processes. Stem c research for the treatment of Parkinson's disease represents most promising alternative.
Neural transplantation in animal models or patients w Parkinson's disease is based on the perspective that there is cure and the current treatment is centred on the pharmacologi relief of symptoms and its secondary consequences (Wheat et al., 2002) . The stem cell implantation method may per the re-establishment of the dopaminergic connections in striatal pathway. Preclinical studies have shown that embryo stem cells are capable of surviving and producing dopam in the host tissue (Bjorklund et al., 2002; Hagell & Brund 2001; Lindvall, 2002) . It is well established that embryo mesencephalic tissue transplants survive in human Parkinson brains. The successful results in clinical trials show that c replacement therapy is viable (Lindvall & Hagell, 2002) .
However, a number of questions remain to be answer One of these is whether implants are able to promote f recovery of very specific affected brain areas. Some reports bilateral implanted tissue into the putamen showed that 30 40% of patients presented symptom reduction and higher lev of the marker f-dopa in the putamen, suggesting graft survi (Hagell & Brundin, 2001; Lindvall & Hagell, 2002) . Desp these findings, the level of recovery measured was only 50 (Hagell & Brundin, 2001; Lindvall & Hagell, 2002) . Ot important issues need to be addressed, such as the mechanis controlling cell differentiation, survival and migration af grafting as well as in vitro, sites of implantation and amo of cells to be grafted.
Most scientists working with Parkinson's disease o consider the engraftment to be successful if the implanted ce present the dopamine releasing machinery and morphologi and physiological characteristics of adult neurones (Galvin Jones, 2002; Hagell & Brundin, 2001; Lindvall & Hagell, 200 The current neural transplantation research in PD patients has been carried out using foetal material obtained from donors whose pregnancy was interrupted (Freed et al., 2001; Lindvall, 1995; Lindvall et al., 1989) . Although there are few reports of stem cell grafting in PD patients (Levesque, 2004) , it seems that this is the most promising treatment and the successful implantation of foetal tissue has shown proof of principle. Parkinson's disease consumes billions of dollars worldwide every year and has a profound impact on the patient's quality of life. Preclinical and clinical studies have shown that neural transplantation of stem cells for Parkinson's offers a promising perspective. It is the most advanced cell replacement therapy for the CNS so far. Although some concern still remains, the promise of successful stem cell replacement therapy gives grounds for hope.
Prospective cell therapy for Alzheimer's disease
Alzheimer's disease (AD) is a neurodegenerative pathology characterized by neuronal degeneration. AD has unknown causes that lead to gradual death of the cells located in the nucleus basalis of Meynert and its pathway to the neo-cortex (Butcher & Woolf, 1986; Whitehouse et al., 1982; Whitehouse et al., 1983) . Although all neurotransmitter systems are affected in AD, the cholinergic system is recognized as the first to be damaged and lose cells (Butcher & Woolf, 1986; Davies & Maloney, 1976; Perry et al., 1978) . Other neuropathological events are hallmarks of the disease, such as beta amyloid deposition and formation of intracellular neurofibrillary tangles, that can only be shown in post-mortem histological analysis (Vickers et al., 2000) .
AD's main symptom is progressive memory degeneration (Katzman, 1989) . The World Health Organization estimates that there are currently about 18 million people worldwide suffering from AD. Projections suggest that this number will nearly double to 34 million by 2025; much of this increase will take place in the developing countries due to population aging as a result of improvement in health conditions (Gauthier, Burns, & Pettit, 1997) .
Cholinergic circuitry reconstruction represents the main objective for cell therapy in Alzheimer's disease (Oliveira & Hodges, 2005) . Animal models using induced lesion of the cholinergic projection system show analogue disruptions of behavioural and cognitive performance similar to those observed in patients, such as memory loss, attention deficit, anxiety, mood instability and learning difficulty (Cummings, 2000; Davis et al., 1999; Muir, Page, Sirinathsinghji, Robbins, & Everitt, 1993) . In such models, the implantation of stem cells has shown promising results, with amelioration of memory loss (Grigoryan, Gray, Rashid, Chadwick, & Hodges, 2000; Sugaya, 2005; Wang et al., 2006) .
As Alzheimer's disease usually affects elderly people and a stem cell engraftment procedure would probably involve surgical intracranial intervention, all cases must be very well for patients. In a preclinical study, Oliveira and colleag (2000) showed that rats with lesions to the basal forebr had their memory and learning performance ameliorated af receiving grafts of either immortalized murine stem cell li or human stem cells into the cholinergic projection (Grigory et al., 2000; Oliveira, Grygorian, & Hodges, 2000b; Oliveira al., 2002) . Results showing improved performance in cognit tasks suggest that Alzheimer's disease may be a target for fut treatment with stem cells (Grigoryan et al., 2000; Suga 2005; Sugaya & Brannen, 2001; Wang et al., 2006) . Howev in order to achieve these aims, several important steps ne to be taken, and research will certainly play a major role this development (Blesch & Tuszynski, 2004; Fernandez al., 2004) . Greater understanding of the neurobiological a molecular factors that determine the progress of the dise will probably be the key to the development of safe treatme for patients.
Prospective cell therapy for stroke
Genetic, dietary and life style elements, such smoking, represent risk factors for cerebral vascu accidents (CVAs), which affect patients in all age rang education or family background. The most comm cerebral ischemic insults result from vascular disturban blood supply interruption and consequent cell death due metabolic and nutritive deficiency. Stem cell therapy m be used in an attempt at revascularization and circui reconstruction.
Some preclinical studies have demonstrated that neu stem cells grafted directly to the brain migrate to the inju areas (Hodges et al., 2000; Modo, Cash et al., 2002) . Th and other studies showed significant improvement several behavioural tests suggesting functional recov (Modo, Cash et al., 2002; Modo, Rezaie et al., 20 Sinden et al., 1997; Veizovic, Beech, Stroemer, Wats & Hodges, 2001) . The influence of grafted stem cells the action of particular proteins that may be involved the regeneration process has also been investigated. F example, Modo observed that the apolipoprotein E ApoE, which is a protein involved in neuro-protecti increased in several regions of the brain after neural st cell grafting. These authors also demonstrated that Ap was expressed in host astrocytes and grafted cells (Mo Hopkins, Virley, & Hodges, 2003) .
Recently, a research group reported a successful bo marrow stem cell based treatment on an ischemic pati (Freitas, André, & Mendez-Otero, 2005; . The cells used in this procedure were intravenou infused and although the procedure might not be conside an implantation, the results were reported as promising.
To better understand the effects of stem cell grafts this sort of injury, continuous scientific investigation i the neurochemical and molecular mechanisms involv in the relationship between grafted cells and host tiss
Prospective cell therapy for spinal cord injury
Spinal cord injuries render the victim partially or completely physically disabled. The incidence may vary from country to country, however, falling accidents are the most common cause followed by car accidents, stabbings or shootings, and sports backbone accidents (Kennedy, Rogers, Speer, & Frankel, 1999; Oller et al., 1992; Scher, 1998; Turgut, Akpinar, Akalan, & Ozcan, 1996; Vogel & Anderson, 2003) . The variety of insults that can cause spinal injury may also lead to different types of damage and disability. For many, spinal cord injury is the greatest challenge for any kind of treatment aimed at central nervous system repair. Successful treatment is not simple and implies a reconstruction of long axonal connections and regeneration of communication in the nervous system.
The degeneration of transected axons leads to the necrotic deterioration of distal axons following disconnection from the cell body. Furthermore, a spinal insult is typically associated with inflammatory responses and the formation of astrocytic scar tissue, which provides a barrier to regenerative regrowth. This, associated with changes in the capacity of such glial scars to secrete and remove toxic molecules from their environment, further impedes the regenerative process. Other important events take place, such as the formation of the so-called "syrinx", which are cysts filled with cerebrospinal fluid that expand in both rostral and caudal directions resulting in further development of symptoms progressively affecting more levels of the cord (Brodbelt & Stoodley, 2003) .
For spinal cord insults, the most studied repair strategy involving stem cells is the implantation of cells directly into the affected area, which is aimed at promoting the rebuilding of functional circuitry by bridging over the glial scar (Cizkova, Rosocha, Vanicky, Jergova, & Cizek, 2006; Hendricks et al., 2006; Ishii et al., 2006; Nishio et al., 2006; Urdzikova et al., 2006) . Both stem cell and tissue implantation therapy programs target the re-myelination of existing neurones, helping them to return to their functional status (Cizkova et al., 2006; Hendricks et al., 2006; Ishii et al., 2006; Nishio et al., 2006; Okano et al., 2003; Rezvani et al., 2001; Urdzikova et al., 2006) . Another possibility is to graft the stem cells before glial scarring takes place, and thus maximize the differentiation of the cells into neurones and myelinating oligodendrocytes.
Grafting before the glial scar is completely formed is another possibility that takes advantage of trophic and inflammatory signals and may direct neuronal and oligodendrocytic differentiation. Some studies have reported these signals acting when the implantation occurred nine days after lesion, but not when the implants happened immediately after the lesion (Ogawa et al., 2002) . It is very important that survival and differentiation of the implanted cells are guaranteed. It is fundamental that the implanted cells have a stimulating environment to promote after injury producing axonal regrowth, establishing c connection and promoting functional benefit (Iwana et al., 2005; McDonald et al., 1999; Nishio et al., 20 Ogawa et al., 2002) . Also, initial clinical trials have be reported presenting promising results (Kang et al., 200 Such results may reinforce great hope among patie suffering from serious disabling conditions. However, in any experimental preclinical study, there are still seve aspects that need further investigation.
Conclusions
Stem cell therapy is a research field with promis prospects for the treatment of central nervous system conditio These cells have the potential to develop into many types a subtypes of cells and are capable of in vitro long-term survi and self-renewal. These properties enhance their therapeu capacity and availability for transplantation. Althou the presence of stem cells in the adult brain has been w documented (Cameron & McKay, 1998; Gage, 2002; Ga Kempermann, Palmer, Peterson, & Ray, 1998; Lim, Flam Collado, & Herrera, 2002; Ray, Palmer, Suhonen, Takahas & Gage, 1997) , due to developmental restrictions, neuro cells are rarely renewed and most probably not in restorat quantities. Therefore, stem cell engraftment therapy may sta out as an alternative for cell replacement in CNS injur and diseases.
The use of embryonic or adult (post-natal) stem cells grafting is currently in open debate all over the world. T discussion about the therapeutic use of stem cells and sources has been held on ethical and scientific perspectiv and will certainly determine the future of research a therapy. Resolving certain technical issues such as vitro and in vivo cell control, accessibility and availabil either of embryonic, foetal or adult cells will help to hav definitive choice of source and methods for clinical use
The way to solve at least part of these problems is curren being tested in different laboratories. Some studies sh successful cell control by genetic modification through introduction of oncogenes capable to control cell division un certain conditions (Jat et al., 1991; Nakafuku & Nakamu 1995; Noble et al., 1993; Noble, Groves, Ataliotis, Ikram, & 1995) . Regarding the problems with stem cell sources, it see that the methods for adult stem cell collection are already u in the clinical practice and, therefore, pose less ethical concer Methods similar to those used in bone marrow transplantat or umbilical cord blood collection can be used to obtain ad stem cells. However, there is a general claim that embryo stem cells have a greater potential because of their totipoten Although the potentiality of stem cells from different source still a topic for debate among scientists, there is little doubt t further research is needed to better understand the potential different cell types for transplants.
Several experiments have demonstrated that gra of stem cells are capable to ameliorate a variety host immunoreactions or mechanisms regulating these functions, are still to be addressed. In the laboratory, SC's can be differentiated into specific cell types lacking neurological conditions and then implanted. In spite of that, one of the most attractive characteristics of SC's is their ability to react to the host tissue and interact with other cells after implantation (Sinden et al., 1997) . Cell replacement is dependent on several factors. Migration and differentiation capacity, as well as cell interaction and integration with the host, are a matter of investigation and cannot completely explain functional recovery in preclinical studies. Although it seems crucial that differentiated cell derivatives must function in a physiologically normal way, this is not the most important issue. Scientists have to resist the pressure to establish SC's therapy as definitive and ready solution. In the current stage, a setback can easily produce serious delays in research funding, as seen with foetal tissue transplants for Parkinson's disease (Check, 2003; Olanow et al., 2003) .
Also, the costs of clinical trials are high and there are several other important issues that need to be carefully considered. Although preclinical studies furnish information on important basic mechanisms involved in stem cell grafting, there are some technical points that can only be resolved with clinical trials. It is possible that many patients may volunteer for such a promising restorative therapy; however, their health condition is often poor and getting worse. It is important to make it clear that stem cell research is still an experimental procedure and serious preclinical and clinical trials have to be carried out. Although only a few successful clinical studies have been performed, it does not seem to be overenthusiastic to say that many currently untreatable neurological conditions will soon be treatable using these techniques.
